Stereotaxis (STXS) Depreciation & Amortization (CF) (2010 - 2026)
Stereotaxis (STXS) posted quarterly Depreciation & Amortization (CF) of $159000.0 for Q1 2026, up 1.92% year-over-year from $156000.0 in Q1 2025, and up 0.63% quarter-over-quarter from $158000.0 in Q4 2025.
Stereotaxis (STXS) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $159000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 1.92% year-over-year to $159000.0; the TTM figure through Mar 2026 stood at $629000.0 (up 4.31% YoY), while the FY2025 annual figure was $626000.0, up 6.64% from the prior year.
- Depreciation & Amortization (CF) climbed to $159000.0 in Q1 2026 per STXS's latest filing, from $158000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $160000.0 in Q1 2023 and bottomed at $94000.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $140941.2 across 5 years, with a median of $150000.0 in 2023.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 403.85% in 2022 and fell as far as 94.12% in 2022.
- Stereotaxis' Depreciation & Amortization (CF) stood at $131000.0 in 2022, then climbed by 5.34% to $138000.0 in 2023, then gained by 15.22% to $159000.0 in 2024, then slipped by 0.63% to $158000.0 in 2025, then climbed by 0.63% to $159000.0 in 2026.
- Business Quant data shows STXS's Depreciation & Amortization (CF) at $159000.0 in Q1 2026, $158000.0 in Q4 2025, and $156000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 192.30 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 564.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 44.78 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 256.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | - |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 133.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 95.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 239.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 159,000.00 |
| Mar 31, 2026 | 159,000.00 |
| Dec 31, 2025 | 158,000.00 |
| Dec 31, 2025 | 158,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Sep 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 156,000.00 |
| Jun 30, 2025 | 156,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Jun 30, 2024 | 136,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Dec 31, 2023 | 138,000.00 |
| Dec 31, 2023 | 138,000.00 |